Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy Felzartamab is an investigational, fully human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results